title: Balancing immunity and immunosuppression: vaccinating patients receiving treatment with efalizumab.
abstract: Although effective in the treatment of immunodysregulatory diseases such as psoriasis, targeted immunosuppressive agents may confer risks of both enhanced susceptibility to infection and decreased responsiveness to vaccination. In a recent study, Krueger et al. (this issue) investigated these issues by testing the immune response to both a model antigen and a therapeutic vaccination in psoriasis patients during and after treatment with an LFA-1 inhibitor, efalizumab.
authors.affiliation: Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA.
authors.forename: Shana
authors.initials: S
authors.lastname: Marmon
authors.affiliation: Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA. Electronic address: strober@nyc.rr.com.
authors.forename: Bruce E
authors.initials: BE
authors.lastname: Strober
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D010584:Bacteriophage phi X 174 / Q000276:immunology; D040881:CD11a Antigen / Q000378:metabolism; D006801:Humans; D007109:Immunity; D007074:Immunoglobulin G / Q000378:metabolism; D007075:Immunoglobulin M / Q000378:metabolism; D007165:Immunosuppression Therapy; D016169:Lymphocyte Function-Associated Antigen-1 / Q000276:immunology; D022242:Pneumococcal Vaccines / Q000494:pharmacology; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013745:Tetanus Toxoid / Q000494:pharmacology; D014612:Vaccines / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D040881:CD11a Antigen; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D016169:Lymphocyte Function-Associated Antigen-1; D022242:Pneumococcal Vaccines; D013745:Tetanus Toxoid; D014612:Vaccines; C472181:efalizumab